Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib Following CAR T-Cell Therapy in Hematologic Malignancies
NCT05044039Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of duvelisib in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Toxicity as measured by number of adverse events at 212 days. Started Feb 2022; status: active, not recruiting.
02
Drugs
duvelisib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05044039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044039.